RT Journal Article
SR Electronic
T1 Risk Prediction In Long Term Kidney Transplant Recipients – Model Development Using Apelinergic Markers And Machine Learning Tools
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.29.24308114
DO 10.1101/2024.05.29.24308114
A1 Batko, Krzysztof
A1 Sączek, Anna
A1 Banaszkiewicz, Małgorzata
A1 Małyszko, Jolanta
A1 Koc-Żórawska, Ewa
A1 Żórawski, Marcin
A1 Niezabitowska, Karolina
A1 Siek, Katarzyna
A1 Bętkowska-Prokop, Alina
A1 Krzanowski, Marcin
A1 Krzanowska, Katarzyna
YR 2024
UL http://medrxiv.org/content/early/2024/05/30/2024.05.29.24308114.abstract
AB Introduction Limited tools exist for predicting kidney function in long-term kidney transplant recipients (KTRs). Elabela and apelin are APJ receptor agonists that constitute the apelinergic axis, which is a recently discovered system regulating vascular and cardiac tissue, in opposition to renin-angiotensin-aldosterone.Methods Longitudinal, observational cohort of 102 KTRs who maintained graft function ≥24 months, with no acute rejection history or current active or chronic infection. Serum apelin, elabela, fibroblast growth factor 23 (FGF-23) and α-Klotho were tested using enzyme-linked immunoassay and compared with a control group of 32 healthy volunteers.Results Median (IQR) follow-up time was 83 (42, 85) months. Higher serum FGF-23 and elabela, but lower α Klotho concentrations were observed in KTRs. Most KTRs had stable trajectories of renal function. All candidate markers were significantly associated with mean two-year eGFR over follow-up, which itself was validated respective to ‘death with functioning graft’ censored dialysis requirement. Using a cross-validation approach, we demonstrated eGFR at initial visit as the most salient predictor of future renal function. Machine learning models incorporating both clinical and biochemical (candidate markers) assessments were estimated to explain 15% of variance in future eGFR when considering eGFR-independent predictions.Conclusions Utilization of machine learning tools that incorporate clinical information and biochemical assessments, including serum amrkers of the apelinergic axis, may help stratify risk and aid decision making in the care of long term KTRs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The conduct of this study was in adherence with the Declaration of Helsinki principles, as well as International Conference on Harmonization/Good Clinical Practice regulations. Study approval was obtained from the Bioethics Committee of the Jagiellonian University and all patients provided written informed consent prior to study inclusion.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.